miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). Recent evidence supports the role of microRNA-223 (miR-223) in modulati...

Descripción completa

Detalles Bibliográficos
Autores principales: HAN, JING, ZHAO, FENGYI, ZHANG, JING, ZHU, HAIZHEN, MA, HU, LI, XUETAO, PENG, LINA, SUN, JIANGUO, CHEN, ZHENGTANG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809653/
https://www.ncbi.nlm.nih.gov/pubmed/26936292
http://dx.doi.org/10.3892/ijo.2016.3401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809653/
https://www.ncbi.nlm.nih.gov/pubmed/26936292
http://dx.doi.org/10.3892/ijo.2016.3401

Ejemplares similares